Alison P Klein1,2,3, Ralph H Hruban1,2, Aatur D Singhi1, Hiroyuki Ishida1, Syed Z Ali1, Michael Goggins1,4, Marcia Canto4, Christopher Wolfgang1,2,5, Zina Meriden1, Nicholas Roberts1. 1. The Sol Goldman Pancreatic Cancer Research Center and Department of Pathology, Johns Hopkins University School of Medicine. 2. Department of Oncology, Johns Hopkins University School of Medicine. 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 4. Department of Medicine, Johns Hopkins University School of Medicine. 5. Department of Surgery, Johns Hopkins University School of Medicine.
Abstract
BACKGROUND: It is estimated that approximately 10% of pancreatic cancers have a familial component. Many inheritable genetic syndromes are associated with increased risk of pancreatic cancer, such as Peutz-Jeghers syndrome, hereditary breast-ovarian cancer and familial atypical multiple mole melanoma, but these conditions account for only a minority of familial pancreatic cancers. Previous studies have identified an increased prevalence of noninvasive precursor lesions, including pancreatic intraepithelial neoplasia, in the pancreata of patients with a strong family history of pancreatic cancer. A detailed investigation of the histopathology of invasive familial pancreatic cancer could provide insights into the mechanisms responsible for familial pancreatic cancer, as well as aid early detection and treatment strategies. METHODS: We have conducted a blinded review of the pathology of 519 familial and 651 sporadic pancreatic cancers within the National Familial Pancreas Tumor Registry. Patients with familial pancreatic cancer were defined as individuals from families in which at least a pair of first-degree relatives have been diagnosed with pancreatic cancer. RESULTS: Overall, there were no statistically significant differences in histologic subtypes between familial and sporadic pancreatic cancers (p > 0.05). In addition, among surgical resection specimens within the study cohort, no statistically significant differences in mean tumor size, location, perineural invasion, angiolymphatic invasion, lymph node metastasis and pathologic stage were identified (p > 0.05). CONCLUSIONS: Similar to sporadic pancreatic cancer, familial pancreatic cancer is morphologically and prognostically a heterogeneous disease.
BACKGROUND: It is estimated that approximately 10% of pancreatic cancers have a familial component. Many inheritable genetic syndromes are associated with increased risk of pancreatic cancer, such as Peutz-Jeghers syndrome, hereditary breast-ovarian cancer and familial atypical multiple mole melanoma, but these conditions account for only a minority of familial pancreatic cancers. Previous studies have identified an increased prevalence of noninvasive precursor lesions, including pancreatic intraepithelial neoplasia, in the pancreata of patients with a strong family history of pancreatic cancer. A detailed investigation of the histopathology of invasive familial pancreatic cancer could provide insights into the mechanisms responsible for familial pancreatic cancer, as well as aid early detection and treatment strategies. METHODS: We have conducted a blinded review of the pathology of 519 familial and 651 sporadic pancreatic cancers within the National Familial Pancreas Tumor Registry. Patients with familial pancreatic cancer were defined as individuals from families in which at least a pair of first-degree relatives have been diagnosed with pancreatic cancer. RESULTS: Overall, there were no statistically significant differences in histologic subtypes between familial and sporadic pancreatic cancers (p > 0.05). In addition, among surgical resection specimens within the study cohort, no statistically significant differences in mean tumor size, location, perineural invasion, angiolymphatic invasion, lymph node metastasis and pathologic stage were identified (p > 0.05). CONCLUSIONS: Similar to sporadic pancreatic cancer, familial pancreatic cancer is morphologically and prognostically a heterogeneous disease.
Authors: Randall E Brand; Markus M Lerch; Wendy S Rubinstein; John P Neoptolemos; David C Whitcomb; Ralph H Hruban; Teresa A Brentnall; Henry T Lynch; Marcia I Canto Journal: Gut Date: 2007-10 Impact factor: 23.059
Authors: Chanjuan Shi; Alison P Klein; Michael Goggins; Anirban Maitra; Marcia Canto; Syed Ali; Richard Schulick; Emily Palmisano; Ralph H Hruban Journal: Clin Cancer Res Date: 2009-12-15 Impact factor: 12.531
Authors: G H Su; R H Hruban; R K Bansal; G S Bova; D J Tang; M C Shekher; A M Westerman; M M Entius; M Goggins; C J Yeo; S E Kern Journal: Am J Pathol Date: 1999-06 Impact factor: 4.307
Authors: Gloria M Petersen; Mariza de Andrade; Michael Goggins; Ralph H Hruban; Melissa Bondy; Jeannette F Korczak; Steven Gallinger; Henry T Lynch; Sapna Syngal; Kari G Rabe; Daniela Seminara; Alison P Klein Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-04 Impact factor: 4.254
Authors: P Langer; P H Kann; V Fendrich; N Habbe; M Schneider; M Sina; E P Slater; J T Heverhagen; T M Gress; M Rothmund; D K Bartsch Journal: Gut Date: 2009-05-25 Impact factor: 23.059
Authors: Thomas P Potjer; Ingrid Schot; Peter Langer; Johannes T Heverhagen; Martin N J M Wasser; Emily P Slater; Günter Klöppel; Hans M Morreau; Bert A Bonsing; Wouter H de Vos Tot Nederveen Cappel; Mathias Bargello; Thomas M Gress; Hans F A Vasen; Detlef K Bartsch Journal: Clin Cancer Res Date: 2012-11-21 Impact factor: 12.531
Authors: Antonio Pea; Jun Yu; Neda Rezaee; Claudio Luchini; Jin He; Marco Dal Molin; James F Griffin; Helen Fedor; Shahriar Fesharakizadeh; Roberto Salvia; Matthew J Weiss; Claudio Bassi; John L Cameron; Lei Zheng; Aldo Scarpa; Ralph H Hruban; Anne Marie Lennon; Michael Goggins; Christopher L Wolfgang; Laura D Wood Journal: Ann Surg Date: 2017-07 Impact factor: 12.969
Authors: Danielle Hutchings; Zhengdong Jiang; Michael Skaro; Matthew J Weiss; Christopher L Wolfgang; Martin A Makary; Jin He; John L Cameron; Lei Zheng; David S Klimstra; Randall E Brand; Aatur D Singhi; Michael Goggins; Alison P Klein; Nicholas J Roberts; Ralph H Hruban Journal: Mod Pathol Date: 2019-07-08 Impact factor: 7.842
Authors: Alexis L Norris; Nicholas J Roberts; Siân Jones; Sarah J Wheelan; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Ralph H Hruban; Alison P Klein; James R Eshleman Journal: Fam Cancer Date: 2015-03 Impact factor: 2.375
Authors: Elizabeth D Thompson; Nicholas J Roberts; Laura D Wood; James R Eshleman; Michael G Goggins; Scott E Kern; Alison P Klein; Ralph H Hruban Journal: Mod Pathol Date: 2020-07-23 Impact factor: 7.842
Authors: Jun Yu; Yoshihiko Sadakari; Koji Shindo; Masaya Suenaga; Aaron Brant; Jose Alejandro Navarro Almario; Michael Borges; Thomas Barkley; Shahriar Fesharakizadeh; Madeline Ford; Ralph H Hruban; Eun Ji Shin; Anne Marie Lennon; Marcia Irene Canto; Michael Goggins Journal: Gut Date: 2016-07-18 Impact factor: 23.059
Authors: Claudio Luchini; Lodewijk A A Brosens; Laura D Wood; Deyali Chatterjee; Jae Il Shin; Concetta Sciammarella; Giulia Fiadone; Giuseppe Malleo; Roberto Salvia; Valentyna Kryklyva; Maria L Piredda; Liang Cheng; Rita T Lawlor; Volkan Adsay; Aldo Scarpa Journal: Gut Date: 2020-04-29 Impact factor: 31.793